favipiravir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals 4887 259793-96-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • favipiravir
  • avigan
  • T-705
A pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase. Several studies reported the use of favipiravir for the treatment of COVID-19 but additional data are needed to substantiate the initial reports. Given the lack of pharmacokinetic and safety data for the high favipiravir dosages proposed for treatment of COVID-19, the drug should be used with caution at such dosages.
  • Molecular weight: 157.10
  • Formula: C5H4FN3O2
  • CLOGP: 1.02
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 89.10
  • ALOGS: -1.26
  • ROTB: 1

Drug dosage:

DoseUnitRoute
1.60 g O

ADMET properties:

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Pharmaceutical products:

None

favipiravir